# US 2013/0274270 A1 · Polymorphs of 3-chloro-4[(2r)-2-(4-chlorophenyl)-4-[(1r)-1-(4-cyanophenyl)ethyl]-1-piperazinyl]-benzonitrile, pharmaceutical compositions and method of use comprising said polymorphs, and a process for preparing them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274270 A1
- Document ID: US20130274270A1
- Status: Published application
- Kind: A1
- Application number: 13/995,389
- Filed: 2011-12-21
- Published: 2013-10-17
- Earliest claimed: 2010-12-23
- Inventors: Monika Brink; Hans-Peter Niedermann; Marcus Knell; Tao Feng; Scott T. Trzaska; Arthur J. Cooper; Shaileshkumar Ramanial Desai; Vinayak Keshav Gore
- Web page: https://patentgrep.com/patent/US20130274270A1

## CPC

- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- C07C 253/30: by reactions not involving the formation of cyano groups
- C07C 255/58: containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C 303/28: by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
- C07C 309/66: Methanesulfonates
- C07D 241/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 309/12: only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Polymorphs of 3-chloro-4[(2R)-2-(4-chlorophenyl)-4-[(1R)-1-(4-cyanophenyl)ethyl]-1-piperazinyl]-benzonitrile are disclosed, as well as pharmaceutical compositions comprising said polymorphs, methods of using the polymorphs, and a process for preparing them.

## Claims

### Claim 1

A crystalline polymorph of Compound A of the formula:
wherein, said polymorph is
Form 3 that exhibits a powder x-ray diffraction pattern substantially the same as the pattern shown in FIG. 3.

### Claim at position 2

2-9. (canceled)

### Claim 10

A crystalline polymorph Form III of Compound A of the formula:
that exhibits a powder x-ray diffraction pattern having characteristic peak locations of 17.9, 21.9, 24.5 and 26.8 degrees 2θ.

### Claim 11 (depends on 10)

The crystalline polymorph Form III of claim 10 that exhibits a powder x-ray diffraction pattern having characteristic peak locations of 7.3, 13.4, 17.9, 19.2, 21.9, 24.5, 25.2 and 26.8 degrees 2θ.

### Claim 12 (depends on 10)

The crystalline polymorph Form III of claim 10 that exhibits a powder x-ray diffraction pattern having characteristic peak locations of 7.277, 12.898, 13′.398, 17.900, 19.238, 20.100, 21.058, 21.625, 21.939, 24.501, 25.179 and 26.800 degrees 2θ.

### Claim at position 6

13-17. (canceled)

### Claim 18

The crystalline polymorph Form III of Compound A that exhibits a melt substantially the same as shown in the differential scanning calorimetry scan of FIG. 6.

### Claim 19 (depends on 18)

The crystalline polymorph Form III of claim 18 having a characteristic melt of 154.8° C.

### Claim at position 9

20-21. (canceled)

### Claim 22 (depends on 1)

A process for preparing the polymorph Form III of claim 1 from Compound A:
comprising the steps of:
a. mixing Compound A at elevated temperature with a first quantity of an organic solvent to form a mixture;
b. adding water portion-wise until precipitate is detected;
c. adding a second quantity of the organic solvent;
d. heating the mixture to about 70° C.; and
e. allowing the mixture to stand at room temperature until Form III crystals precipitate.

### Claim 23 (depends on 22)

The process of claim 22 wherein the organic solvent is n-propanol.

### Claim 24 (depends on 22)

The process of claim 22 wherein the ratio of the first quantity to the second quantity is about 2:1.

### Claim 25 (depends on 1)

A pharmaceutical composition comprising a crystalline polymorph of Form III, of claim 1, and at least one pharmaceutically acceptable excipient or carrier.

### Claim 26 (depends on 1)

A purified form of the polymorph of claim 1.

### Claim 27 (depends on 1)

A method of treating obesity and obesity-related diseases in an animal in need of such treatment, comprising administering to said animal an effective amount of at least one polymorph of claim 1.

### Claim 28 (depends on 27)

The method of claim 27 wherein the animal is a dog.

### Claim 29 (depends on 27)

The method of claim 27 further comprising the administration of at least one additional anti-obesity agent.

### Claim 30

A process for preparing the compound of formula II
comprising:
reacting the protected amino ethanol 1b and 4-chloro-styreneoxide (2b), wherein Ph is phenyl and THP is tetrahydropyranyl, to obtain compound 3b;
reacting compound 3b and 4-amino-3-chlorobenzonitrile (4b) in the presence of methanesulfonyl chloride and a base to obtain compound 5b;
removing the THP protecting group from compound 5b and converting the product to a salt (6b);
treating compound 6b with methanesulfonyl (Ms) chloride and a base to obtain compound 7b;
cyclizing compound 7b by treating with sodium hydroxide to obtain 8b;
removing the benzyl protecting group from compound 8b; and
reacting compound 9b with compound 10b, wherein Pr is a protecting group, in the presence of potassium carbonate.

### Claim 31 (depends on 30)

The process of claim 30 for preparing the compound of the Formula A
comprising:
reacting the protected amino ethanol 1 and 4-chloro-styreneoxide (2), wherein Ph is phenyl and THP is tetrahydropyranyl, to obtain compound 3;
reacting compound 3 and 4-amino-3-chlorobenzonitrile (4) in the presence of methanesulfonyl chloride and a base to obtain compound 5;
removing the THP protecting group from compound 5 and converting the product to a salt (6)
treating compound 6 with methanesulfonyl (Ms) chloride and a base to obtain compound 7;
cyclizing compound 7 by treating with sodium hydroxide;
removing the benzyl protecting group from compound 8; and
reacting compound 9 with compound 10, wherein Pr is a protecting group, in the presence of potassium carbonate.

### Claim 32 (depends on 31)

The process of claim 31 comprising:
reacting the protected amino ethanol 1 and 4-chloro-styreneoxide (2) at about 125° C. to obtain compound 3;
reacting compound 3 and 4-amino-3-chlorobenzonitrile (4) in 2-methyl-tetrahydrofuran the presence of methanesulfonyl chloride and triethylamine to obtain compound 5;
removing the THP protecting group from compound 5 and converting the product to the HCl or p-toluenesulfonic (p-TOS) salt (6)
treating compound 6 with methanesulfonyl (Ms) chloride and triethylamine to obtain compound 7;
cyclizing compound 7 by refluxing with sodium hydroxide;
removing the benzyl protecting group from compound 8 by treating with 1-chloroethyl chloroformate; and
reacting compound 9 with compound 10 in the presence of potassium carbonate.

### Claim 33

A process for preparing compound A
comprising:
cyclizing compound 7 by treating with sodium hydroxide to obtain compound 8;
removing the benzyl protecting group from compound 8; and
reacting compound 9 with compound 10 in the presence of potassium carbonate.

### Claim 34

A compound selected from the group consisting of

### Claim 35 (depends on 34)

The compound selected from the group of claim 34, wherein the compound is
